Noveris Provides Announces Trading Halt Order, And Clarification As To Article

Vancouver, British Columbia, March 26, 2026 – TheNewswire – Noveris Health Sciences Inc. (the “ Company ”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) announces that the British Columbia Securities Commission (“ BCSC ”) issued an order dated March 25, 2026 under section 89(1) of the Securities Act (British Columbia) halting all trading in the Company's securities until April 16, 2026 (the “ Order ”) due to, among other matters, unexplained and unusual fluctuations in the volume of trading in, or market price, of the Company's shares traded on the CSE. The full text of the Order can be viewed on www.sedarplus.ca. The Company also wishes to clarify that the Company has not authorized, commissioned, or otherwise been involved in the creation or distribution of an article concerning the Company circulated by John Michaels on March 19, 2026 (the “ Article ”).  The Company further confirms that neither the Company nor its investor relations service provider was aware of the Article prior to its publication, and neither has any relationship or affiliation with the individual or entities responsible for its authorship or dissemination. The Company did not provide information, commentary, review, approval, or input of any kind. Any statements, claims, or opinions expressed in the Article should not be construed as having been reviewed, verified, endorsed, or supported by the Company.  In particular, the Article states that “the company is FDA-registered”.  To the extent “FDA” refers to U.S. Food and Drug Administration, this statement is inaccurate.  The Company does not have any registrations with the Food and Drug Administration, nor is actively pursuing any applications for registration for any of its products at this time. The Company refers readers to its public disclosure, which remains current, and confirms that it has no material undisclosed information at this time.